FDA rejects PTC's Friedreich’s ataxia drug

The FDA rejected PTC Therapeutics’ Friedreich’s ataxia drug vatiquinone, the company announced Tuesday morning. The agency said that “substantial evidence of efficacy” was not shown for the Friedreich’s ataxia therapy, according to PTC’s press release ...